Obermatt
See Similar Stocks →

Richter Gedeon

BUD:RICHTER · HU0000123096
PharmaceuticalsLarge

360

93
EV / EBIT100
Price / Owner Earnings89
Owner Earnings Yield96
Dividend Yield97
Price/Sales69
EV / Gross Profit82
Price/Book70
Return on Capital75
Cash Return on Capital77
Return on Equity63
EBIT Margin90
Gross Profitability32
Cash Conversion50
Accruals37
Owner Earnings Margin89
Sales growth27
Profit Growth76
Long-Term EPS Growth14
Owner Earnings Growth45
Reinvestment21
Price momentum54
Debt load70
Refinancing91
Debt Payback100
Liquidity74
Analyst ratings16
Opinion Changes13
Price Target Upside48
Market mood83
Value Creation20/20strong value creator
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Richter Gedeon generates returns well above its cost of capital, the foundation of durable shareholder value.

Profile

CountryHungary
IndustryPharmaceuticals
SizeLarge
TypePublic Company
ExchangeBUSE
Employees1,976
Websitegedeonrichter.com/hu-hu
ISINHU0000123096
Last UpdateApr 2, 2026
Index & Theme
CardiovascularPain ManagementReproductive HealthNeurologyWomen's HealthImmunologyCentral Nervous SystemBiotechnologyHealth CarePharmaceutical

Description

Gedeon Richter PLC manufactures pharmaceutical products. The company focuses on the development, production, and marketing of prescription drugs, over-the-counter products, and veterinary medicines. Business Segments The company operates mainly thr…

Analysis

Bargain bin

Gedeon Richter PLC is priced cheaply, and that invites the natural question of why, since the underlying business scores below average.

On valuation, the picture is attractive. The owner-earnings multiple stands at 9.5×; owner earnings: the cash an owner could take out each year.

Growth is moderate; the safety picture is sturdy. The company scores 20/20 on our value-creation score: strong value creator.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
88
2023202420252026

All-time high

100

Jan 2025

All-time low

88

Mar 2026

Average rank

96

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
69
37
56
64
Price/Earnings
50
91
91
78
Price/Book
70
61
76
76
Dividend Yield
97
96
98
98
Value (overall)
91
96
99
94

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Richter Gedeon with its peers
Sandoz
SWX:SDZ
18
CountrySwitzerland
IndustryPharmaceuticals
SizeX-Large
Full Stock Analysis →
Curatis Holding
SWX:CURN
70
CountrySwitzerland
IndustryPharmaceuticals
SizeX-Small
Full Stock Analysis →
Cohance Lifesciences
NSI:COHANCE
37
CountryCyprus
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Sanofi India
NSI:SANOFI
56
CountryFrance
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Dermapharm
GER:DMP
39
CountryGermany
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Cosmo Pharmaceuticals
SWX:COPN
47
CountryIreland
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →